JPMorgan analyst Anupam Rama downgraded Cidara Therapeutics (NASDAQ: CDTX) from Overweight to Neutral with a price target of $221.50 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE